膠原腫における全生存率を予測するための潜在的なバイオマーカーとしての膠原系の変化の非侵襲的評価
Qian Li1, Xuetong Tao1, Xuanle Li1,2
11Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Journal of neurosurgery
|September 5, 2025
まとめ
ALPS指数で測定されるリンパ機能の低下は,攻撃的な膠原腫と生存時間の短縮に関連しています. この非侵襲的なMRI分析は,膠原腫患者の予後値を提供します.
科学分野:
- 神経イメージング
- 腫瘍学
- 放射線科
背景:
- グリオマは予後が変動する原発性脳腫瘍です.
- ゴミの除去に不可欠なリンパ系 (GS) の機能は,膠原腫で変化することがあります.
- GS機能の非侵襲的評価は予後評価のために必要である.
研究 の 目的:
- ALPS指数を用いて,拡散性膠原腫におけるリンパ機能の変化を評価する.
- 膠原腫患者のALPS指数と放射線学的特徴の予後値を探る.
主な方法:
- UCSF-PDGMデータセットの遡及分析 (グレード2〜4のグリオマの患者437人)
- 非侵襲的なGS分析のための拡散MRIによるALPS指数の計算.
- 放射性特性の抽出とALPS指数と生存率との相関
主要な成果:
- リンパ機能の低下 (ALPS指数の低下) は,より高度のIDHワイルド型および1p19q無傷の膠原腫と関連していました.
- ALPS指数が低いと生存時間が短かった (HR 0. 297, p < 0. 001).
- ALPS指数と放射線学を組み合わせることで 生存率の予測の精度が向上しました
結論:
- リンパ系機能の障害は,より攻撃的な膠原腫のサブタイプと関連しています.
- ALPS指数は,グリオマの価値ある非侵襲的予後バイオマーカーとして機能します.
- ALPSインデックスを放射線学と統合すると,膠原腫患者の予後能力が向上します.
さらに関連する動画
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.0K
09:17Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022
2.4K
関連する概念動画
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Mismatch Repair
5.4K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.4K
Mutagenicity and Carcinogenicity
2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
